Lupin launches Paliperidone extended-release tablets in the United States

Lupine Limited today announced the launch of Paliperidone Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg, 9 mg, as a generic counterpart to Janssen Research and Development, Invega Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg and 9 mg.

In the United States, paliperidone extended-release tablets (RLD Invega) projected annual sales of US$112 million (IQVIA MAT August 2022).

The company is a market leader in the cardiovascular, anti-diabetes, and respiratory sectors, and also has a significant presence in the anti-infective, gastrointestinal (GI), central nervous system (CNS) and women’s health sectors. Lupine is the third largest pharmaceutical company in the United States by prescriptions.

At around 1.38 pm, Lupine was trading at Rs 678.25, down 1.43% from its previous close of Rs 688.10 on the Bahrain Bourse. The stock touched the highest and lowest prices of the day at Rs 691 and Rs 670.65 respectively.

For comments and suggestions, write to us at [email protected]